CRIS Current Research Information System

FINELLI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.738
EU - Europa 2.104
AS - Asia 1.145
AF - Africa 199
Continente sconosciuto - Info sul continente non disponibili 15
SA - Sud America 4
OC - Oceania 3
Totale 6.208
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.731
GB - Regno Unito 627
CN - Cina 395
IT - Italia 372
SE - Svezia 354
VN - Vietnam 286
DE - Germania 274
SG - Singapore 243
IN - India 105
TG - Togo 93
IE - Irlanda 82
RU - Federazione Russa 76
FR - Francia 74
JP - Giappone 65
ZA - Sudafrica 54
EE - Estonia 52
NG - Nigeria 41
UA - Ucraina 37
HR - Croazia 35
BG - Bulgaria 27
JO - Giordania 23
BE - Belgio 21
CH - Svizzera 19
FI - Finlandia 19
EU - Europa 15
AT - Austria 12
CI - Costa d'Avorio 9
NL - Olanda 8
CA - Canada 6
UZ - Uzbekistan 6
IR - Iran 5
GR - Grecia 4
LB - Libano 4
TR - Turchia 4
BR - Brasile 3
RO - Romania 3
AU - Australia 2
CZ - Repubblica Ceca 2
HK - Hong Kong 2
IL - Israele 2
PL - Polonia 2
SC - Seychelles 2
AZ - Azerbaigian 1
BD - Bangladesh 1
CR - Costa Rica 1
DK - Danimarca 1
EC - Ecuador 1
KG - Kirghizistan 1
KR - Corea 1
LU - Lussemburgo 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
RS - Serbia 1
Totale 6.208
Salva come PNG Salva come JPEG
Città #
Southend 590
Fairfield 306
Chandler 300
Ashburn 253
Singapore 211
Houston 190
Ann Arbor 156
Santa Clara 142
Wilmington 142
Bologna 138
Seattle 135
Woodbridge 130
Princeton 117
Cambridge 101
Lomé 93
Dong Ket 82
Dublin 80
Boardman 76
Padova 59
Westminster 55
Nanjing 53
Abeokuta 41
Tokyo 40
Jinan 35
Shenyang 35
Redwood City 34
Saint Petersburg 34
Beijing 33
Medford 32
Changsha 29
Berlin 27
Sofia 27
Milan 25
Amman 23
Hebei 23
Nanchang 23
New York 22
Turin 22
Brussels 21
Helsinki 19
Bern 15
San Diego 15
Jiaxing 14
Falls Church 13
Menlo Park 12
Hangzhou 11
Norwalk 11
Vienna 11
Bremen 10
Tappahannock 10
Tianjin 10
Abidjan 9
Dearborn 9
Guangzhou 9
Florence 8
Jacksonville 8
Shanghai 8
Valsamoggia 8
Bühl 7
Haikou 7
Rome 7
Mountain View 6
Taizhou 6
Zhengzhou 6
Andover 5
Lanzhou 5
Los Angeles 5
Amsterdam 4
Hefei 4
Ningbo 4
Busto Arsizio 3
Cesena 3
Des Moines 3
Lausanne 3
Merano 3
Provo 3
Sacramento 3
São Paulo 3
Taglio Di Po 3
Taiyuan 3
Zola Predosa 3
Asaka 2
Bentivoglio 2
Brescia 2
Buffalo 2
Calderara Di Reno 2
Colton 2
Dallas 2
Den Haag 2
Forlì 2
Foshan 2
Gussago 2
Holon 2
Hong Kong 2
Istanbul 2
Kiev 2
Kunming 2
Langfang 2
Las Vegas 2
Leawood 2
Totale 4.282
Salva come PNG Salva come JPEG
Nome #
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 215
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 204
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 195
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 159
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 158
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 156
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 149
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 148
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 147
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 144
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 141
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS 139
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 133
Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. 132
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 131
Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. 125
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 124
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 123
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 122
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 122
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 117
Nuclear inositide signaling in myelodysplastic syndromes. 116
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 113
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 112
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 112
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 111
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 110
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 110
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 106
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 104
null 103
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 102
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 102
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 102
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 101
Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. 100
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 98
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 95
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 95
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 93
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. 85
Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera. 83
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 83
GENE EXPRESSION OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS IN MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 81
ROLE OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS ON EPO-INDUCED EYTHROID DIFFERENTIATION IN LOW-RISK MDS PATIENTS 81
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 80
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 77
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 76
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 74
null 72
null 71
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 70
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 68
Long-lasting hematologic response to azacitidine in myelodysplastic syndromes: Multicenter retrospective study of 36 patients 65
null 43
null 41
null 35
PI-PLCBETA1 GENE METHYLATION AND EXPRESSION AS A RELIABLE AND DYNAMIC MARKER OF CLINICAL RESPONSE TO 5-AZACYTIDINE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES 30
PROSPECTIVE PHASE II STUDY ON LOW-DOSE 5-AZACYTIDINE FOR TREATMENT OF SYMPTOMATIC PATIENTS WITH LOW/INT-1 RISK MYELODISPLASIA 29
IS PI-PLC 1 EXPRESSION A RELIABLE PREDICTOR OF RESPONSE IN LOW RISK MDS PATIENTS TREATED WITH LOW-DOSE AZACITIDINE? RESULTS OF A PROSPECTIVE MULTICENTRIC STUDY 28
PKR is activated in MDS patients and its subcellular localization depends on disease severity. 16
Totale 6.357
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.361
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.361
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.115 0 0 0 0 139 154 141 167 242 89 91 92
2020/2021829 155 39 11 26 24 33 36 33 78 31 27 336
2021/20221.128 121 16 57 97 98 72 36 49 39 150 177 216
2022/20231.310 102 177 77 183 116 96 60 118 209 13 100 59
2023/2024417 22 58 33 36 51 71 14 15 26 60 13 18
2024/2025568 48 150 87 77 206 0 0 0 0 0 0 0
Totale 6.357